StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck noxafil (posaconazole, legacy) — Worldwide reported growth YoY (%) (%)

Form 8-K Table 3 / 3a / 3b Product Sales

QuarterlyAnnual
Latest, Q4 2024
-23.0%
Period ended Dec 31, 2024
Change on a year earlier
-2.0 pts
-21.0% in Q4 2023
History
28 quarters
Since Q4 2017
Sources
28
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNoxafil (posaconazole, legacy) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q4 2024Dec 31, 2024-23.0%-2.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024-20.0%-2.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 2024-20.0%-12.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-7.0%-12.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 2023-21.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 2023-18.0%-15.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 2023-8.0%0.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 20235.0%+19.0 ptsForm 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 2022-3.0%+16.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 2022-8.0%+2.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 2022-14.0%+15.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 2021-25.0%-5.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 2021-19.0%+36.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q2 2021Jun 30, 2021-10.0%+52.0 ptsForm 8-K (tm2123400d1_ex99-1.htm, filed 2021-07-29) ↗
Q1 2021Mar 31, 2021-29.0%+21.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 2020-20.0%+26.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗

Cite this data

StockData. (2026). Merck Noxafil (posaconazole, legacy) — Worldwide reported growth YoY (%) (%), quarterly Q4 2017–Q4 2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_noxafil_ww_nom_yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.